Organized by Helsinki University Hospital Comprehensive Cancer Center/Dept. of Hematology, Clinical Research Institute HUCH and The Finnish Leukemia Group.
Date: Thursday February 16, 2017
Location: Biomedicum Helsinki, lecture hall 2, Haartmaninkatu 8
PROGRAM
| 08:30 | Coffee | |
| 08:50 | Welcome and introduction | Kimmo Porkka Professor, Helsinki University Hospital Comprehensive Cancer Center |
| Session I: State of the art (chair: K. Porkka) | ||
| 09:00 | Novel therapy options for AML | Richard M. Stone Professor, Dana-Farber Cancer Institute, Boston, MA |
| 09:40 |
Towards curative drug therapy for Ph+ALL |
Farhad Ravandi |
| 10:20 | Coffee, exhibitions | |
| 10:40 |
Role of novel antibodies in multiple myeloma |
Pieter Sonneveld |
| 11:20 |
Update on CAR T-cell therapy |
Justin Eyquem Research fellow, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY |
| 12:00 | Lunch | |
|
Sessio II: SHY:n Veritautien hoito- ja tutkimusryhmä (pj Raija Silvennoinen) |
||
| 13:00 |
Suomen myeloomaryhmä (FMG)
|
|
| 13:45 | Suomen Leukemiaryhmä: AML-update |
Maija Itälä-Remes |
| 14:00 | Hemofiliaryhmä | Anne Mäkipernaa |
| 14:15 | Nordic CML Study Group: update | Perttu Koskenvesa |
| 14:30 | PNH-ryhmä | Elina Armstrong |
| 14:45 | Päätössanat | Kimmo Porkka |
Eeva Lind-Ekholm (eeva.lind-ekholm@hus.fi, 09-471 74581) 03.02.2017 mennessä. Mainitsethan samalla mahdollisesta erityisruokavaliosta.
Welcome! Tervetuloa!